Post-hoc of ARASENS for metastatic ho... - Advanced Prostate...

Advanced Prostate Cancer

22,263 members27,955 posts

Post-hoc of ARASENS for metastatic hormone sensitive prostate cancer

Maxone73 profile image
20 Replies

sciencedirect.com/science/a...

in a nutshell:

1 - Deep and Durable PSA Response: The combination therapy produced a significant number of patients achieving undetectable PSA levels (<0.2 ng/ml). Approximately 67% of the patients reached undetectable PSA at some point, with variations based on disease volume—62% in high-volume and 84% in low-volume disease subgroups.

2 - Time to PSA Progression: Darolutamide extended the time to PSA progression substantially compared to placebo, with hazard ratios indicating a significant risk reduction in both high- and low-volume disease groups.

3 - Clinical Outcomes and PSA Suppression: Achieving undetectable PSA levels correlated strongly with longer overall survival (OS) and delayed progression to castration-resistant prostate cancer (CRPC). In particular, undetectable PSA levels at weeks 24 and 36 after treatment initiation were associated with improved outcomes, emphasizing the importance of reaching and maintaining low PSA levels.

4 - Safety Profile: The therapy was well-tolerated, with adverse events aligning with those expected for the treatments used.

Written by
Maxone73 profile image
Maxone73
To view profiles and participate in discussions please or .
Read more about...
20 Replies
janebob99 profile image
janebob99

Excellent Summary. Thanks !

KocoPr profile image
KocoPr

i love darolutamide.

Maxone73 profile image
Maxone73 in reply toKocoPr

Let's hope it loves us back!

Justfor_ profile image
Justfor_

"... importance of maintaining low PSA levels". That's the reason for my preference to a low drug maintenance dosing instead of any on-off intermitent cycling.

KocoPr profile image
KocoPr in reply toJustfor_

Is your goal to keep PSA as low as possible?

I worry that i would eventually get castrate resistance thus that is why i do BAT. My way of saying this is to keep the beast fed and happy on T and keep it caged with Daro/ADT

Justfor_ profile image
Justfor_ in reply toKocoPr

Not as low as possible because I want to know the way things are developing. For this, PSA has to be at the lowest reportable range, that is 0.010 to 0.050. If by increasing Bicalutamide dosage PSA goes down, or alternatively by reducing it goes up, I know it is still doing its job, hence resistance isn't brewing up.

MateoBeach profile image
MateoBeach in reply toKocoPr

Working great in my modified BAT regimen KocoPr. See my details below in this thread.

KocoPr profile image
KocoPr in reply toMateoBeach

I had a temporary setback on my BAT program due to kidney stone snd high Uric Acid which spiked my PSA big time. On Daro/ADT again which dropped PSA like rock. OC and I will readdress at next visit in Dec. my plan is to reset the PSA then try your cBAT again. I will write a post soon on FPC group

AlvinSD profile image
AlvinSD

Thank you for posting this. I was diagnosed 5/22 and did triplet therapy with darolutamide then finished it off with radiation

Grateful for this community because without it I would have never met Tall_Allen who pushed me to add chemotherapy based on the (at the time) newly released ARASENS trial data.

MateoBeach profile image
MateoBeach

Darolutamide plus ADT is such a great combo for mHSPC as these results show. This should move the FDA to remove the requirement for concomitant docetaxel chemotherapy for this treatment regimen in those who were not de novo metastatic.

I use Orgovyx plus Darolutamide in my low to no Testosterone phase of modified BAT. Three months of high T, 2400 ng/dL (2-3 x nl) for 3 months then one month on ADT plus Darolutamide. My PSA remains <.015 during low T, and only up to .020 on the high T.

Rcole727 profile image
Rcole727

Thanks for posting this. Im somewhat confused. I read the ARANOTE trial which I thought evaluated daroluamide and ADT without chemo in patients with high or low volume mHSPC which I thought concluded that ARANOTE and ARASENS demonstrated efficacy benefits with darolutamide plus ADT with and without docetaxel for patients with mHSPC. For myself, my mHSPC is not denovo as I had Proton in 2009 for PC with Gleason 6 and 1 core 7 (3+4). Im currently on doublet therapy- Firmagon and Nubeqa.

Maxone73 profile image
Maxone73 in reply toRcole727

I would say that your conclusions are right...where is the confusion? 😀

Rcole727 profile image
Rcole727 in reply toMaxone73

I was advised that doublet therapy- Firmagon & Neubeqa -is less effective than Triplet therapy even if individual mHSPC is not denovo.

Maxone73 profile image
Maxone73 in reply toRcole727

eh, I don't know if there is a direct comparison, plus (luckily for us) the last time both trials were updated, they had not reached median for OS yet (I think also for rPFS, but I should check), for non de novo it seems that they want to keep the chemo card for later

Rcole727 profile image
Rcole727 in reply toMaxone73

Much appreciate your analysis!

StayingOptimistic profile image
StayingOptimistic in reply toMaxone73

I was offered doublet by MSK and I am on vacation for almost a year now.

Maxone73 profile image
Maxone73 in reply toStayingOptimistic

And how is Psa?

StayingOptimistic profile image
StayingOptimistic in reply toMaxone73

Undetectable

Maxone73 profile image
Maxone73 in reply toStayingOptimistic

Great result!!!!

gsun profile image
gsun in reply toRcole727

ARASENS was with Docetaxel. ARANOTE Is without.

Not what you're looking for?

You may also like...

Abiraterone in Metastatic Hormone-Sensitive Prostate Cancer

TAKE-HOME MESSAGE •This is a post-hoc analysis of the STAMPEDE study, where the outcomes of...
Balsam01 profile image

Patterns of Cancer Progression of Metastatic Hormone-sensitive PCa in the ECOG3805 CHAARTED Trial

New CHAARTED paper below [1]. "Reliance on prostate-specific antigen (PSA) alone is an inadequate...
pjoshea13 profile image

Patterns of Cancer Progression of Metastatic Hormone-sensitiveProstate Cancer in the ECOG3805 CHAARTED Trial

"ECOG3805 is a randomized trial of testosterone suppression with or without docetaxel for...
tango65 profile image

Metformin: Preliminary Results of Trial in Advanced Prostate Cancer (MANSMED)

Not sure if this was posted here yet: In a mini-oral presentation at this year’s European Society...
noahware profile image

Docetaxel vs Surveillance After Radical Radiotherapy for Intermediate- or High-Risk Prostate Cancer

TAKE-HOME MESSAGE •Docetaxel combined with androgen-deprivation therapy (ADT) has improved...
Balsam01 profile image